Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Dateline City:
KENILWORTH, N.J.
KEYNOTE-024 Studied Patients Whose Tumors Expressed High Levels of PD-L1
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the KEYNOTE-024 trial investigating the use of
KEYTRUDA® (pembrolizumab), in patients with previously
untreated advanced non-small cell lung cancer (NSCLC) whose tumors
expressed high levels of PD-L1 (tumor proportion score of 50 percent or
more), met its primary endpoint.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD NYSE:MRK Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Merck | Non-Small Cell Lung Cancer | Pharmaceuticals